Cytomegalovirus (CMV) has been linked with vascular pathology and is a common complication of renal transplantation. We addressed whether CMV seropositivity influences vascular pathology several years after transplant. Levels of CMV antibody increased with age, were higher in transplant recipients than healthy controls (p<0.001) and correlated with vascular endothelial function measured by flow mediated-dilation of the brachial artery (FMD). However the optimal general linear model predicting FMD included CMV seropositivity as a marginal effect (p=0.068), with age (p=0.013), gender (p<0.0001) and transplantation (p<0.0001). Other measures of the burden of CMV are being tested as CMV prophylaxis is feasible.
INTRODUCTION
Most people carry cytomegalovirus (CMV) as a lifelong latent infection, with periodic reactivations triggered by inflammation or stress. CMV is also a common infectious complication of renal transplantation (1) . Before prophylaxis was available, one in three renal transplant recipients (RTR) experienced pathologies associated with CMV. For example; 12 of 141 RTR in one study, died with disseminated CMV infection (2) . In Australia, it is common practice to administer valganciclovir as prophylaxis for 12-26 weeks after transplantation, based on donor and recipient CMV seropositivity and clinical risk. Under a similar regimen, CMV replication was detected in 33% of previously seropositive RTR and 21% of those who were seronegative at transplantation (3) . However the long-term use of valganciclovir after this initial prophylactic period is not standard as there are uncertain benefits and cost. However CMV reactivations are implicated in deterioration in renal function (4) , new onset type II diabetes (5) and vascular pathologies. Cardiovascular disease after renal transplantation is a common long-term complication of successful renal transplantation and is more frequent in CMV-positive patients (6, 7) . Periodic CMV prophylaxis of selected patients stable on anti-rejection therapy is feasible and has the potential to reduce these adverse outcomes.
Several studies associate the presence of CMV-DNA in tissues removed during surgery for abdominal aortic aneurysm with expression of inflammatory mediators (eg: 8). Higher CMV antibody titres are linked with increased blood pressure in young men (9) and coronary artery disease requiring surgery (10). Here we assess whether levels of CMV antibodies or a simple dichotomy of seropositive versus negative independently predict large vessel health assessed by carotid intima media thickness (cIMT) and flow mediated dilatation (FMD) of the brachial artery.
cIMT is an independent predictor of clinical cardiovascular events, including myocardial infarction and stroke (11). Brachial arterial FMD is assessed by high-resolution ultrasound after blood flow is occluded for a few minutes. The measurement reflects endothelium-dependent vasodilator function. It is validated as a surrogate of endothelial function of the coronary circulation, and associates with prevalent and incident cardiovascular disease (12) .
Renal transplant recipients (RTR; n=82) were recruited from the renal clinics at Royal Perth Hospital (RPH), Western Australia. Inclusion criteria were clinically stable >2 years after transplantation, no CMV disease or reactivation within 6 months of blood collection and no antiviral treatment. Age-matched healthy controls (n=81) were recruited through local advertisements.
Demographic details are provided in Table 1 Tetramethylbenzidine substrate (Sigma-Aldrich) was added, colour development was stopped with 1M H 2 SO 4 and plates were read at 450nm. CMV seronegativity was defined using the CMV lysate assay as <3 standard deviations above the mean antibody levels recorded in 11 samples that were seronegative by the ARCHITECT CMV IgG assay (Abbott Diagnostic Systems; Lake Forrest, IL), creating a cut-off of 3623AU/ml. As a few individuals meeting this criterion had antibodies detectable with gB or IE-1, analyses were repeated using cut-offs of 340AU/ml gB and 3500AU/ml IE-1 antibody.
Clinical assessments
To assess cIMT, the common carotid arteries were examined in accordance with guidelines from the American Society of Echocardiography (13) . Briefly; the anterolateral, posterolateral and mediolateral planes were acquired using a 12-15 MHz multi-frequency linear array probe attached to a high resolution ultrasound machine (Aspen, Acuson; Mountain View, CA). Subjects lay supine with a slight hyperextension of the neck and a 45° lateral flexion away from the side scanned. The vessel was scanned to exclude any carotid plaque. An R-wave triggered optimal recording of the far wall, 1cm proximal to the carotid bulb, was directly encoded and stored as a digital DICOM file for post hoc analysis.
After a 10 to 20-minute rest period, brachial artery diameter response to FMD was assessed using a 12-15 MHz multi-frequency linear array probe attached to a high resolution ultrasound machine, (14) . Briefly, subjects lay supine with their arms extended at ~80° from their torso. A rapid inflation/deflation pneumatic cuff was placed around the arm distal to the olecranon process.
When an optimal B-mode image was obtained, images were collected using a fixed insonation angle (<60°). Baseline images were recorded for 1 min, before the forearm cuff was inflated to 220mm Hg for 5mins. Recording resumed 30sec prior to cuff deflation, and continued for 5mins post-deflation. FMD is presented as the relative (%) rise from the baseline diameter.
Diameters were analysed with custom-designed edge-detection and wall-tracking software to minimise investigator bias. Briefly; a region of interest is drawn around the B-mode image of the vessel segment, and the edges are detected automatically. Over 200 individual measurements are taken from each frame. For cIMT analysis, the median value is calculated to represent a single "composite cIMT". Three sets of these composite values from common carotid arteries are used to determine the mean lumen diameter and cIMT. Analyses of the reproducibility gave a CV of 6.7-10.5% for FMD (15) and 3.5% for cIMT (16) .
Statistical analysis
Statistical analyses were performed using Prism 5 (GraphPad Software, La Jolla, CA) and SAS (Version 9.2, 2008; Cary, NC). Univariate comparisons used non-parametric Mann-Whitney tests and Spearman's correlations. Multivariate associations between independent variables (transplantation, age and gender) and measures of CMV antibody (lysate, gB, IE-1) as dependent variables were sought with a separate general linear model (GLM) for each outcome. GLM were then developed with %FMD or maximum cIMT as the outcome, to assess the influence of transplantation, gender, age (in quartiles), BMI (in tertiles), systolic and diastolic blood pressures (in quartiles) and CMV antibodies (in quartiles). Categories were created to assess whether the relationship with %FMD approximated linearity. They were amalgamated where there appeared to be a 'step function' rather than a linear relationship, or removed if the relationship appeared to be linear. In each case, backward elimination was used to obtain the most parsimonious model. A p-value<0.05 was taken to indicate a statistically significant association, but p<0.10 was noted.
RESULTS AND DISCUSSION
The 82 RTR cases and 81 healthy controls were similar in age and gender ( (Table 1) . CMV seropositivity decreased the %FMD in RTR compared with CMV negative RTR (p=0.066), but this effect was not detected in controls.
The optimal GLM (R 2 =0.317, p<0.0001) included the presence of CMV lysate antibody (p=0.068), age >55 years (p=0.013), gender (p<0.0001) and transplantation (p<0.0001). The outcome was similar using CMV gB antibody (R 2 =0.317, p<0.0001 with p=0.065 for gB) but there was no link with CMV IE-1 antibody (R 2 =0.317, p<0.0001 with p=0.381 for IE-1). In all models tested, BMI and blood pressure (systolic or diastolic) showed no significant association with FMD. 
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